Avastin Labeling Will Reflect New Data On Thromboembolic Events

Genentech's "Dear Doctor" letter cites evidence of an "increased risk of serious arterial thromboembolic events" related to use of the oncologic. A revised package insert containing more detailed information on arterial thromboembolic events across five studies is in development, the company says.